A cytokine-based serum proteomic score is a prognostic biomarker for immunotherapy in head and neck cancer
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-025-04271-1 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Md Saiful Islam Saif und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, USA. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Cytokines, Head and Neck Neoplasms, Immunotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIGMS COBRE, National Cancer Institute Cancer Center.
Abstract (Originalsprache)
Despite advances with anti-programmed death (PD)-1-based immunotherapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), identifying who will benefit from these therapies remains challenging. In a prospective, multicenter study, serum levels of 92 cytokines were measured in pretreatment sera collected on 38 (discovery cohort) and 40 (validation cohort) patients with R/M HNSCC undergoing anti-PD-1-based immunotherapy. A prognostic cytokine score comprised of four cytokines (CXCL1, MCP-4, IL6, CD40) was developed using Cox elastic net modeling within the discovery cohort and showed concordance indices of 0.71 and 0.79 for overall survival (OS) in the discovery and validation cohorts, respectively. High cytokine scores were linked to worse OS (p < 0.01, adjusted HR = 2.07, 95% CI = 1.26-3.41). Further, the cytokine score outperformed established biomarkers including TMB and PD-L1 CPS. Our results suggest that serum cytokine proteomic score may serve as prognostic biomarker for anti-PD-1 therapy in R/M HNSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, USA.
- Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
- Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
- Harvard Medical School, Boston, MA, USA.
- Department of Epidemiology, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
- Department of Epidemiology, and Pathology, and Laboratory Medicine, Brown University School of Public Health, Providence, RI, USA.
Förderung
- NCI NIH HHS
- NIGMS COBRE
- National Cancer Institute Cancer Center
- NIGMS NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Saif, M. S. I., Sehgal, K., Zhang, Z., Butler, R. A., Wiencke, J. K., Molinaro, A. M., Miller, J., Stolrow, H. G., Shirai, K., Salas, L. A., Koestler, D. C., Haddad, R., Christensen, B. C., & Kelsey, K. T. (2025). A cytokine-based serum proteomic score is a prognostic biomarker for immunotherapy in head and neck cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04271-1
Vancouver
Saif MSI, Sehgal K, Zhang Z, Butler RA, Wiencke JK, Molinaro AM, et al. A cytokine-based serum proteomic score is a prognostic biomarker for immunotherapy in head and neck cancer. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04271-1
BibTeX
@article{Saif2025,
author = {Saif, Md Saiful Islam and Sehgal, Kartik and Zhang, Ze and Butler, Rondi A and Wiencke, John K and Molinaro, Annette M and Miller, Julianna and Stolrow, Hannah G and Shirai, Keisuke and Salas, Lucas A and Koestler, Devin C and Haddad, Robert and Christensen, Brock C and Kelsey, Karl T},
title = {A cytokine-based serum proteomic score is a prognostic biomarker for immunotherapy in head and neck cancer},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-025-04271-1}
}
EUVIMED